Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Insuplant is a brand name for an insulin product. However, based on the available data from major regulatory and reference sources, there is no widely recognized or approved pharmaceutical product named "insuplant" in the US, EU, or other major markets as of May 2025. The name does not appear among commercially available insulins listed by leading manufacturers such as Eli Lilly, Novo Nordisk, Sanofi, Biocon Biologics, Wockhardt, Lupin, or others[1][3][5]. It is possible that "insuplant" refers to a regional brand of insulin (potentially in India or another market with smaller manufacturers), a discontinued product line not covered by global databases, or it may be a misspelling/misinterpretation of another insulin brand.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on insuplant.